1. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer.
2. Astragaloside III, ononin and astragalosideIV have anti-gastric ulcer effects, also exhibit strong growth-promoting effects in cultured GES-1 cells.
1. Bisdemethoxycurcumin can regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism, also suppresses MCF-7 cells proliferation by inducing ROS accumulation and modulating senescence-related pathways.
2. Bisdemethoxycurcumin directly accelerates gastric ulcer healing with potency equal to curcumin, its antiulcer effect might be due to its properties of decreasing gastric acid secretion and enhancing the mucosal defensive mechanism through suppression of iNOS-mediated inflammation.
3. Bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA.
4. Bisdemethoxycurcumin induces apoptosis in activated HSCs, but not in hepatocytes, by impairing cellular energetics and causing a downregulation of cytoprotective proteins, likely through a mechanism that involves CBR2.
5. Bisdemethoxycurcumin has effects on 12-Ο-tetradecanoylphorbol-13-acetate-induced tumor promotion.
6. Bisdemethoxycurcumin has antioxidant activities, inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions.
1. Coumarin is a potent inducer of aflatoxin B1-aldehyde reductase, has chemoprevention of aflatoxin B1 hepatocarcinogenesis.
2,. Coumarin is an anticoagulant drug.
3. Coumarin has antiulcerogenic activity, it may influence the secretion control mediated by the parasympathetic system.
4. Coumarin and 3-hydroxycoumarin can be a promising class of photoprotective drugs.
1. Naringin exhibits antioxidant effects, it reduces Ara-C-induced oxidative stress through both an inhibition of the generation of ROS production and an increase in antioxidant enzyme activities; it blocks apoptosis caused by Ara-C-induced oxidative stress, resulting in the inhibition of the cytotoxicity of Ara-C.
2. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice, it is a single dietary constituent clinically modulating drug transport.
3. Naringin has anti-atherogenic effects, the effect is involved with a decreased hepatic cholesterol acyltransferase (ACAT) activity and with the downregulation of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemotactic protein-1 (MCP-1) gene expression.
4. Naringin and hesperidin both play important roles in preventing the progression of hyperglycemia, partly by increasing hepatic glycolysis and glycogen concentration and/or by lowering hepatic gluconeogenesis.
5. Naringin has protective effects against post-stroke depression induced neurobehavioral, biochemical and cellular alterations in mice, the nitric oxide mechanism involves in it.
6. Naringin possesses anti-lipoperoxidative and antioxidant activity in experimentally induced cardiac toxicity, has cardioprotective potential.
7. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway, it may be used as a potential supplement for the prevention and treatment of breast cancer.
8. Naringin attenuates epidermal growth factor (EGF)-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IκB-NF-κB signaling pathways.
9. Naringin and lovastatin contribute to hypocholesterolemic action via down-regulated ACAT activity and higher excretion of fecal sterols in response to high-cholesterol feeding, naringin supplement seems to preserve tissue morphology from damages induced by high cholesterol diet.
10. Naringin has antiulcer effects on gastric lesions induced by ethanol in rats.
11. Naringin has protective effect against colchicine-induced cognitive dysfunction and oxidative damage in rats.
1. Marmin can inhibit contraction of the guinea-pig tracheal smooth muscle, especially by interfering histamine receptor, inhibiting the histamine release from mast, inhibiting intracellular Ca2+ release from the intracellular store and the Ca2+ influx through voltage-dependent Ca2+ channels.
2. Marmin, skimmianine, aegeline, aurapten, zeorin, and dustanin are potential to develop as antihistamine agents, especially as histamine H1 receptor antagonists by interacting with amino acid residues, Asp107, Lys179, Lys191, Asn198, and Trp428 of histamine H1 receptor.
3. S-trans-Marmin shows potent antibacterial, fungicidal, and algicidal properties.
4. Marmin shows a cell-growth inhibitory effect against L1210 and K562 in vitro.
5. Marmin and nobiletin have anti-ulcer effects, which are ascribed primarily to the maintenance of the mucosal barrier integrity and inhibition of gastric motor activity and secondarily due to the prevention of the effects of endogenous acetylcholine and histamine.